Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuling Yunhua Granules and Dihuang Baoyuan Granules in Type 2 Diabetes
NCT07920640Phase 2Not yet recruiting
- Sponsor
- Beijing Supreme Life Pharmaceutical Technology Co., Ltd.
- Start
- Nov 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Fuling Yunhua Granules and Dihuang Baoyuan Granules in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Beijing Supreme Life Pharmaceutical Technology Co., Ltd. Primary endpoint: Glycated Hemoglobin at 24 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
Fuling Yunhua GranulesDihuang Baoyuan Granules
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07920640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07920640.